All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2004-004904-19 | A two-centre, open label study of weekly pegvisomant treatment for patients with acromegaly | 2011-05-26 | due-trials |
Reported results | 2004-005184-15 | Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism | 2011-03-23 | due-trials |
Reported results Terminated | 2005-002698-65 | A randomised clinical trial comparing safety and efficacy of topical preparations for the eradication of methicillin resistant staphylococcus aureus (MRSA) compared with a novel preparation based on a... | 2009-11-30 | due-trials |
Not reported | 2005-005660-86 | A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma | 2013-08-05 | due-trials |
Reported results | 2006-000344-10 | Multi-centre study of cabergoline alone and in combination with pegvisomant in the management of active acromegaly | 2010-06-01 | due-trials |
Reported results | 2006-000598-31 | Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma | 2015-11-06 | due-trials |
Reported results Terminated | 2006-001742-13 | Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study) | 2010-09-15 | due-trials |
Reported results | 2006-004989-14 | The Effect of Raloxifene on Serum IGF-I in Patients with Acromegaly on long-term Octeotide Treatment | 2010-11-01 | due-trials |
Reported results | 2006-005566-39 | Concurrent chemoradiotherapy for stage III non small cell lung cancer followed by consolidation pemetrexed: a phase II study | 2010-10-21 | due-trials |
Not reported Terminated | 2007-000741-36 | Study of radiotherapy dose escalation with Intensity Modulated Radiation Therapy (IMRT) and synchronous Cetuximab for intermediate stage head and neck cancer | 2015-05-29 | due-trials |
Reported results Terminated | 2007-002053-24 | A phase II study evaluating the use of concurrent cetuximab, irinotecan, oxaliplatin and UFT in the first line treatment of patients with metastatic colorectal cancer | 2013-05-15 | due-trials |
Reported results Terminated | 2007-004749-14 | Assessing the Feasibility of a Single Blind Randomised Controlled Trial to Measure the Effectiveness of D-Alpha-Tocopherol in the Management of Oral Mucositis in Patients Undergoing Conditioning for B... | 2009-06-30 | due-trials |
Reported results | 2007-005242-21 | A pilot study of replacement therapy with recombinant TSH in central hypothyroidism | 2011-04-08 | due-trials |
Reported results | 2008-000066-22 | A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma | 2013-06-12 | due-trials |
Reported results | 2008-002686-30 | Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease | 2011-09-15 | due-trials |
Reported results Terminated | 2009-011078-14 | A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors. | 2011-11-24 | due-trials |
Not reported | 2009-011377-33 | AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB | 2015-09-26 | due-trials |
Reported results Terminated | 2012-005327-33 | A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer | 2017-11-30 | due-trials |
Reported results | 2013-000139-28 | A single arm double-blind placebo controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: “CALC” Trial | 2014-11-17 | due-trials |
Reported results Terminated | 2013-001071-20 | A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy with Tumour Infiltrating Lymphocytes (TIL) and Assessment of High versus Low Dose Interleukin-2 | 2015-09-15 | due-trials |
Reported results | 2013-001812-30 | A Phase III, randomised, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced/metastatic biliary tract canc... | 2019-01-04 | due-trials |
Other | 2013-002073-22 | A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma( PIANO) | not-yet-due | |
Other | 2013-002466-39 | A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemother... | not-yet-due | |
Exempt, with results Terminated | 2013-005471-40 | PAZOFOS: A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer | 2017-11-21 | not-yet-due |
Other | 2015-003883-36 | Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer | not-yet-due | |
Other | 2017-002453-11 | A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line ... | not-yet-due | |
Other | 2018-004121-80 | A proof of concept, window trial of the IMmunological effects of AveLumab and Aspirin in Triple-Negative Breast Cancer. | not-yet-due | |
Other | 2018-004314-17 | The CAPER study: A Phase Ib clinical trial of Cyclophosphamide And PEmbrolizumab in metastatic Renal cell carcinoma (CAPER Trial) | not-yet-due |